Mdxhealth (r) presentation of new data on mdxhealth’s prostate and bladder cancer products at aua 2018 annual meeting – news press release blood cancer symptoms in adults

May 22, 2018 – MDxHealth SA (Euronext: MDXH.BR) announces that significant data on the performance of its SelectMDx, and ConfirmMDx tests for prostate cancer and AssureMDx test for bladder cancer were presented in two moderated posters and one podium presentation at the American Urological (AUA) Annual Meeting 18-21 May in San Francisco. Details are as follows:

In this evaluation study, the pre- and post-biopsy RNA and DNA biomarker assays SelectMDx and ConfirmMDx outperformed the PCA3 biomarker test. Combining the urinary RNA test with the epigenetic DNA tissue test significantly improved accuracy for the identification of men with high-grade PCa.

The results of the study showed that by using SelectMDx in addition to serum PSA in the diagnostic pathway, Quality Adjusted Life Year (QALY)* benefits could be gained while saving healthcare costs.

Cost savings varied form 129 Euro per patient in the Netherlands up to 1,217 Euro per patient in France. Despite some differences between the countries, a resulting reduction in the prevalence of over-treatment and over-diagnosis under the current standard of care was the main factor leading to beneficial outcomes from use of SelectMDx for risk stratification.

Hematuria patients comprise 20% of all referred patients in the urology clinic. Most hematuria patients will undergo an invasive cystoscopy procedure, but only 3-28% will be diagnosed with bladder cancer. In this prospective validation study of 1004 patients presenting with hematuria, the urine-based bladder cancer test improved the identification of patients most likely to benefit from cystoscopy. Importantly, these results are consistent with published studies, and further demonstrating the robustness of the test.

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.